Login

Join Now

Recent BioUtah News & Events

Everything Happening in Utah Life Sciences

March 7, 2024
BioUtah News
MAUNA KEA TECHNOLOGIES PARTNERS WITH METRODORA TO CREATE FIRST U.S. CENTER OF EXCELLENCE FOR THE USE OF CELLVIZIO® TO IDENTIFY AND TREAT FOOD INTOLERANCE IN ADULTS

Cellvizio Food Intolerance Test (C-FIT) delivers real-time, in vivo visibility to accurately identify food intolerance in patients suffering from Irritable Bowel Syndrome (IBS) Metrodora will serve as Center of Excellence for patient care and physician training to enable broad access to this breakthrough procedure Paris, Boston and Salt Lake City, March 6, 2024 – 5:45 […]

March 7, 2024
BioUtah News
Constant Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of TXA127 in Duchenne Muscular Dystrophy-Associated Cardiomyopathy

BOSTON, March 4, 2024 /PRNewswire/ — Constant Therapeutics LLC, a biopharmaceutical company focused on the development of treatments impacting the Alternative Renin-Angiotensin System, today announced that the first patient was dosed March 3, 2024, in the Company’s phase 2 clinical trial of TXA127, the Company’s lead peptide product under development as a potential treatment for […]

March 7, 2024
BioUtah News
Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink

Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on April 30, 2024 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously […]

March 1, 2024
BioUtah News
Renalytix Expands US Government Coverage for FDA Approved kidneyintelX.dkd Testing at $950

Data to be Presented Today at NGS Open Meeting Demonstrating Clinical Value of KidneyIntelX LONDON and SALT LAKE CITY, February 29, 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) announces that effective March 1, 2024, the United States Government has approved adding the company’s Food and Drug Administration (“FDA”) de Novo Marketing authorized test, kidneyintelX.dkd, to its […]

February 29, 2024
BioUtah News
Utah Legislative Recap, February 29, 2024

Funding Requests   Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry.  BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create […]

February 29, 2024
BioUtah News
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National Cancer Center Hospital East (NCCHE) in […]

February 29, 2024
BioUtah News
Owlet Announces $9 Million Private Placement Financing

LEHI, Utah–(BUSINESS WIRE)– Owlet, Inc. (NYSE: OWLT) (“Owlet” or the “Company”) announced today, following recent FDA clearances and strong preliminary fourth quarter results, that it has entered into definitive documentation relating to a sale of shares of its newly issued Series B convertible preferred stock (“Series B preferred stock”) and warrants to purchase its Class […]

February 26, 2024
BioUtah News
PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

SALT LAKE CITY, Feb. 26, 2024 (GLOBE NEWSWIRE) — PolarityTE today announced the Screening of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational treatment of Wagner grade 1 diabetic foot ulcers (DFUs), entitled “Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE II,” or “COVER DFUS II.” COVER DFUS […]

February 22, 2024
BioUtah News
Utah Legislative Recap: February 23, 2024

Funding Requests Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry.  BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create and […]

February 22, 2024
BioUtah News
EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections

Novel Nanoparticle Platform Shows Efficacy Against Antimicrobial Resistance; Potential to Disrupt the $29 BillionCatheter Market SALT LAKE CITY, Feb. 22, 2024 /PRNewswire/ — EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced its antimicrobial medical device platform has demonstrated effectiveness against the world’s leading pathogens implicated […]

February 22, 2024
BioUtah News
Seek Labs Welcomes Alison O’Mahony, PhD as new Vice President of Pharmaceutical Research

SALT LAKE CITY, UT, February 22, 2024 (BusinessWire) – Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel gene therapies, announced today the appointment of Alison O’Mahony, PhD as Vice President of Pharmaceutical Development. With nearly 20 years of experience in R&D, phenotypic drug discovery, and assay and scientific operations, O’Mahony […]

February 22, 2024
BioUtah News
February 22, 2024
BioUtah News
Thermo Fisher Scientific Announces Latest Round of Oncomine Clinical Research Grant Awardees

Recipients’ research focused on melanoma diagnosis, treatment response in advanced NSCLC, and bypassing common hurdles in NSCLC diagnosis and treatment

February 22, 2024
BioUtah News
Thermo Fisher Scientific Recognized by Customers for Contract Manufacturing Leadership

Pharma and biotech customers distinguish excellence in capabilities, compatibility, expertise, quality and reliability

February 15, 2024
BioUtah News
Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience […]

February 15, 2024
BioUtah News
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

FDA Approval Triggers $225 Million Milestone Payment from Ipsen to Merrimack Merrimack Expects to Hold Special Meeting of Stockholders to Approve Plan of Dissolution in May 2024 Following Approval of Plan of Dissolution, Merrimack Expects to Issue a Liquidating Dividend Currently Estimated to be Between $14.65and $15.35 per Share in the Late Spring or Early […]

February 15, 2024
BioUtah News
PrecisionLife and Metrodora Institute Partner to Accelerate the Diagnosis and Treatment of Long COVID, ME/CFS, and other Chronic Conditions

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases Targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year   OXFORD, UK and SALT LAKE CITY, US – 15 February 2024 – The pioneering precision medicine company, […]

February 15, 2024
BioUtah News
Halia Therapeutics Initiates Phase II Clinical Trial to Evaluate Efficacy of HT-6184, a First-in-Class NEK7/NLRP3 Inhibitor, on Post Procedural Inflammatory and Pain Responses

The first patient undergoing wisdom tooth extraction has been dosed with HT-6184 to evaluate its effect on post-procedure diagnostic biomarkers of inflammation and pain, as well as to evaluate its safety and tolerability. LEHI, Utah, Feb. 15, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, […]

February 15, 2024
BioUtah News
Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System

New guidance system marks significant advancement in breast cancer care, targeting tumor location in multiple dimensions for precise excision and successful surgeries SOUTH JORDAN, Utah, Feb. 15, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, has received US Food and Drug Administration (FDA) 501(k) clearance for the […]

February 15, 2024
BioUtah News
Utah Legislative Recap – February 15, 2024

Utah Legislative Recap – Updated February 15, 2024

February 9, 2024
BioUtah News
Centers for Medicare & Medicaid Services Publishes Draft Local Coverage Determination for KidneyIntelX and kidneyintelX.dkd

LONDON and SALT LAKE CITY, February 9, 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that on February 8, 2024 the Centers for Medicare and Medicaid Services (“CMS”) published a draft Local Coverage Determination (“LCD”) for the Company’s KidneyIntelX and kidneyintelX.dkd testing. The draft LCD can be accessed at https://www.cms.gov/medicare-coverage-database/. The established Medicare price […]

February 8, 2024
BioUtah News
Utah Legislative Recap, Feb. 9, 2024

Funding Requests   Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry.  BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create […]

February 8, 2024
BioUtah News
2024 Life Sciences Day on the Hill Recap

Utah’s vibrant life sciences industry was on full display February 7 as part of BioUtah’s “Life Sciences Day on the Hill”. The event, a collarboration with the Governor’s Office of Economic Opportunity, (GOEO) was held at the state capitol. 29 companies exhibited their innovative technologies in the capitol rotunda, which provided legislators the opportunity to […]

February 8, 2024
BioUtah News
Eris Biotech accepted to Y Combinator

Eris Biotech accepted to Y Combinator